Abdi İbrahim Wins Two International Awards

Operating in the pharmaceutical sector for 109 years with the goal of improving life, Abdi İbrahim continues to crown its success in management and public relations projects on the international stage. At the Stevie International Business Awards, one of the world's most prestigious award platforms in the business world, Abdi İbrahim won bronze awards in two categories. By establishing a strategic partnership with Swiss biotechnology company OM Pharma in September 2020, Abdi İbrahim strengthened its global identity and continues to sustain the same level of success achieved domestically on the international stage. Abdi İbrahim was recognized with bronze awards in two categories at the Stevie International Business Awards, headquartered in the United States. At the Stevie International Business Awards, where leading companies from around the world compete with their projects in various fields, Abdi İbrahim Board Chairman Nezih Barut was recognized with a bronze award in the "Chairman of the Year" category. The evaluation panel assessed candidates in this award category based on the company's performance and leadership demonstrated since the beginning of 2019. Abdi İbrahim Board Chairman Nezih Barut, who received the Stevie award this year in the Chairman of the Board of Directors category, was recognized for numerous achievements including: proactive decisions in the production of medication used in COVID-19 treatment; the rapid production and donation to the Ministry of Health of the drug that appeared worldwide at the onset of the pandemic and was included in initial treatment protocols; investments in biotechnology, a field that continues to grow in importance in the global pharmaceutical sector and stands out in the treatment of diseases that cannot be treated with chemical medications; performance in sustainability and climate change mitigation as the first Turkish pharmaceutical company to share with the public the goal of becoming carbon neutral by 2030 in line with the Paris Agreement principles; and the acquisition of a 28.5% stake in Swiss biotechnology pharmaceutical company OM Pharma in 2020 with a Swiss venture capital group, making it the first and only Turkish pharmaceutical company to establish a strategic partnership with a European pharmaceutical firm. In addition to serving as Board Chairman of Abdi İbrahim, Turkey's leading pharmaceutical company, Nezih Barut has served as chairman of the Pharmaceutical Industry Employers' Union for 13 years. The "Viral Agenda" communication initiative, which shared current and evidence-based medical information needed by everyone during the pandemic period, won a bronze award in the "COVID-19 Related Information" (COVID-19 Response Categories) category in the Year's Communication/Public Relations Campaign category. Winners were announced on 16 August, and the Stevie Awards will be presented to recipients at an online ceremony on 8 December.

Award-Winning Project: Viral Agenda Provides Access to Accurate COVID-19 Information

Since 2002, the Stevie International Business Awards, presented in 8 different divisions with relevant subcategories, receive nominations from more than 12,000 individuals, companies, projects and initiatives. Abdi İbrahim placed two awards on the winners list determined following the evaluation of a panel consisting of 260 professional judges from around the world this year. The Viral Agenda communication initiative, which won a bronze award in the Year's Communication/Public Relations Campaign field, was launched to eliminate misinformation during the pandemic and address the need for access to accurate information. The Viral Agenda project, which aimed to deliver current and scientific information primarily to physicians, healthcare workers and the general public in more accessible language, involved scanning hundreds of articles on COVID-19 appearing worldwide each week to prepare the most accurate content. Viral Agenda, prepared by a team of doctors from various specialties within Abdi İbrahim's Medical Directorate, was regularly distributed weekly via email, LinkedIn, Twitter, Facebook and Instagram to both 4,600 employees within the company and the target audience. Through this project, the spread of unscientific or unverified information was also prevented.